Asterias Biotherapeutics (AST) Sees Large Volume Increase

Asterias Biotherapeutics Inc (NYSEAMERICAN:AST) saw an uptick in trading volume on Thursday . 1,068,768 shares traded hands during mid-day trading, an increase of 154% from the previous session’s volume of 420,289 shares.The stock last traded at $2.45 and had previously closed at $2.15.

A number of research analysts have recently weighed in on AST shares. HC Wainwright reissued a “buy” rating on shares of Asterias Biotherapeutics in a research note on Wednesday, November 22nd. Zacks Investment Research raised shares of Asterias Biotherapeutics from a “hold” rating to a “buy” rating and set a $2.75 price objective for the company in a research note on Wednesday, October 25th. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. Asterias Biotherapeutics currently has an average rating of “Hold” and an average price target of $9.19.

The firm has a market capitalization of $132.67, a P/E ratio of -3.85 and a beta of 1.30.

ILLEGAL ACTIVITY NOTICE: This piece of content was first posted by Transcript Daily and is the property of of Transcript Daily. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of international trademark & copyright legislation. The legal version of this piece of content can be accessed at

Asterias Biotherapeutics Company Profile

Asterias Biotherapeutics, Inc is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors.

Receive News & Ratings for Asterias Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asterias Biotherapeutics and related companies with's FREE daily email newsletter.

Leave a Reply